Navigation Links
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Date:8/6/2008

f-of-concept trial noted outlined above. With the positive initial results from that clinical trial and the decision to move forward to a Phase 2b outpatient clinical trial in migraine patients, Alexza must file a new IND with the DNP. It is projected that the Company will file this new IND in the fourth quarter of 2008 and initiate our Phase 2b outpatient study in the first quarter of 2009. AZ-104 has been licensed to Symphony Allegro, and Alexza has the right to repurchase all rights to this product candidate.

-- AZ-002 (Staccato alprazolam). Alexza is developing AZ-002 for the acute treatment of panic attacks associated with panic disorder. In June 2008, the Company announced the top line results of our in-clinic, single-center, double-blind, placebo-controlled, Phase 2a proof-of-concept clinical trial in patients with panic disorder. The primary aim of the clinical trial was to assess the safety and efficacy of a 1 mg single dose of AZ-002 in treating a pharmacologically-induced panic attack. Differences versus placebo in the intensity and the duration of a panic attack were collected at multiple time points during the study using psychological and physiological measurements. The study did not meet its two primary endpoints, which were the effect of AZ-002 on the incidence of a doxapram-induced panic attack and the effect of AZ-002 on the duration of a doxapram-induced panic attack, both as compared with placebo. There were no serious adverse events in the clinical trial, and AZ-002 was safe and well tolerated in the study patient population.

Thorough pharmacokinetic and pharmacodynamic analyses from this study show that alprazolam was administered in an IV-like manner with the Staccato system. Similar blood levels were observed in this study as were recorded during the AZ-002 Phase 1 PK and safety study in normal volunteers. Alexza and Symphony Allegro are completing work on the Phase 2a program for AZ-002 in acute panic attack. Following this com
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 30, 2014 Migranade, Inc. announced today the ... to the 36 million U.S. migraine sufferers November, 2014. ... targets the actual cause of migraines and not just ... not the source Migranade is assured to be a ... Relief is available at http://www.migranade.com and will ...
(Date:10/31/2014)... 31, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... , Isis Pharmaceuticals, Third Quarter 2014 Financial Results ... at 11:30 a.m. ET / 8:30 a.m. PTWhere: ... Internet. Simply log onto our website listed above. If ... a replay of the webcast will be available for ...
(Date:10/30/2014)... CHARLOTTETOWN , Oct. 30, 2014 /CNW/ - Atlantic ... three-year agreement reached between Canada,s ... Jim Keon , President of the Canadian Generic Pharmaceutical ... made the comments while speaking at the Atlantic Summit ... Charlottetown , which is being hosted by the ...
Breaking Medicine Technology:Game Changing Migraine Medication To Be Available November 2014 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 3
... N.J., Aug. 1, 2011 Social stigma is the ... care physicians, according to a survey commissioned by Janssen ... the National Medical Association (NMA).(1) Despite the belief by ... very serious or a crisis in the African-American community, ...
... Reportlinker.com announces that a new market research ... Prefilled Syringes: Devices, Therapeutics, Players, ... http://www.reportlinker.com/p0581168/Prefilled-Syringes-Devices-Therapeutics-Players-Markets-and-Prospects .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... continues to grow, the issue of prefilled ...
Cached Medicine Technology:Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds 2Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds 3Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds 4Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects 2Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects 3
(Date:10/31/2014)... — A team from the Broad Institute, the ... California, Santa Cruz, was awarded one of three ... contracts with the goal of building a system ... Genome Atlas (TCGA) and other datasets by co-locating ... one cloud environment. This co-location will enable researchers ...
(Date:10/31/2014)... October 31, 2014 At the start ... families narrowly escaping carbon monoxide poisoning in their homes. ... weeks away, one family-owned, Missouri-based heating and cooling company ... making sure families start the home heating season with ... secure. , Beginning Nov. 1, 2014, E and ...
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Sleep apnea may make ... where you parked your car or left your house keys, ... severe sleep apnea showed that this ability -- called spatial ... movement (REM) sleep, even when other stages of sleep weren,t ... which dreams typically occur. "We,ve shown for the first ...
(Date:10/31/2014)... a lab device to give cancer researchers an unprecedented ... cells spread through the body, causing more than 90 ... how tumor cells travel, the device could uncover new ... from the university,s Whiting School of Engineering and its ... their new system recently in the journal Cancer ...
(Date:10/31/2014)... combination that can trigger the self-destruct process in lung ... according to research that will be presented at the ... next week*. , When healthy cells are no longer ... self destruction. But cancer cells swerve away from this ... grow out of control – causing tumours to form. ...
Breaking Medicine News(10 mins):Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 2Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 3Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... have found that an active lifestyle with limiting TV time ... conducted in the US TV watching results in a lower ... games, reading, writing or driving a car. Prolonged TV watching ... are focussed on increasing exercise and hardly concentrate on reducing ...
... whether daily moderate exercise could actually prevent Heart disease. ... hiking, climbing stairs, racket sports and swimming does really ... disease. Recommendations in the United States and elsewhere say ... sufficient for good heart health.// A World Health Organization ...
... that mice lacking a specific immune cell are unable to ... (AHR) which is narrowing of the tiny passages in the ... mite. AHR is triggered by the immune system and leads ... attack. Researchers at Stanford University have been studying mice that ...
... health of their children most expecting moms will do whatever needs ... of rest. But are those moms who smoke, ready to set ... moms willing to put their habit on ,hold for the sake ... recent meeting of the Baxter County Tobacco Control Committee was ,that// ...
... particularly those who are breastfed, should be given vitamin D ... the bones fail to grow straight and strong. While breast ... contain enough vitamin D to meet babies needs. This happens ... of the vitamin D. All infant formula sold in the ...
... now studied a new electrical device,that might lead ... Parkinson's disease.,This new treatment involves implanting an electrical ... for Parkinson's patients. This,electrical device helps stimulate both ... otherwise cause disabling tremor. The researchers ran a ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: